News

TheraNym Biologics Is India's Largest Dedicated Biologics CMO — Aurobindo's Hyderabad Facility Is Now Open, With MSD as Anchor Customer and $175M Unit 2 Already Planned

By Mustafa Shariff, Editor in Chief · August 5,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — TheraNym Biologics Is India's Largest Dedicated Biologics CMO — Aurobindo's Hyderabad Facility Is Now Open, With MSD as Anchor Customer and $175M Unit 2 Already Planned

Summary

  • TheraNym Biologics: Aurobindo's Hyderabad Facility Opens as India's Largest Biologics CMO With MSD Anchor Customer and $175M Unit 2 Planned
  • Aurobindo Pharma inaugurated TheraNym Biologics in Borapatla, Hyderabad on June 3, 2026 — India's largest dedicated biologics CMO featuring 15 KL bioreactors and MSD as anchor customer, followed immediately by a $150-175M Unit 2 expansion announcement.

"TheraNym represents a defining moment in large-scale biologics manufacturing in India and a proud milestone for Aurobindo Pharma. India has the scientific talent, the manufacturing expertise, and now the infrastructure to be a global leader in biologics — not just in generics. MSD's confidence in TheraNym as an anchor customer is a validation of our capabilities and our commitment to international regulatory standards. This is the beginning of India's biologics century."

Aurobindo Pharma inaugurated TheraNym Biologics — one of India's largest dedicated biologics contract manufacturing organisations — at its facility in Borapatla, Telangana, on June 3, 2026. The inauguration was held in the presence of Shri D. Sridhar Babu, Minister for IT, Industries and Commerce and Legislative Affairs, Telangana, and Shri Damodar Raja Narasimha, Minister for Science and Technology of Telangana. Prior to the inauguration, Aurobindo Pharma's leadership team and senior executives from MSD met with Telangana Chief Minister Shri Anumula Revanth Reddy to discuss the project.

TheraNym Biologics has been designed and equipped as a world-class dedicated biologics CMO — a distinction from Aurobindo Pharma's main manufacturing business, which focuses on small-molecule generics, APIs, and finished dosage forms. The dedicated biologics CMO infrastructure at TheraNym includes 15 KL (kilolitre) bioreactors for mammalian cell culture manufacturing, advanced downstream purification systems, aseptic fill-finish capabilities, and modern quality control laboratories — all designed and constructed to meet the international regulatory standards of the US FDA, EMA, and other major regulatory authorities.

MSD as Anchor Customer: The Commercial Validation
MSD (Merck Sharp and Dohme, the international trade name of Merck & Co., Inc.) has been announced as the anchor customer for TheraNym — the commercial relationship that provides the facility with its primary commercial mandate and validates its capability in the eyes of the global pharmaceutical market. MSD's relationship with Aurobindo through TheraNym builds on a partnership originally established in May 2024 for biologics manufacturing collaboration, and its anchor customer status signals confidence that TheraNym's manufacturing standards, quality systems, and regulatory readiness meet MSD's supply chain requirements.

Dr. Dave Maraldo, Executive Vice President and President of MSD Manufacturing Division, was present at the inauguration — a signal of the seniority of MSD's institutional commitment to the TheraNym partnership. The commercial arrangement involves TheraNym manufacturing and supplying biologic drug substances to MSD for both domestic and international markets, subject to applicable regulatory approvals.

Unit 2: Immediately After Opening, the $150-175M Expansion
The operational launch of TheraNym was immediately followed by the announcement of a major expansion — Unit 2 — a greenfield facility that will install 60,000 litres of mammalian cell culture bioreactor capacity alongside advanced downstream purification systems. The investment in Unit 2 is approximately $150-175 million, and the project reflects an additional product schedule under TheraNym's existing contract manufacturing agreement with MSD — meaning the Unit 2 expansion is commercially anchored by MSD's expanded biologics manufacturing requirements.

The combination of TheraNym's operational 15 KL bioreactor facility and the planned 60,000 litre Unit 2 expansion positions Aurobindo as one of the largest-scale biologics CMO operators in India — with total bioreactor capacity that, at full operation, would rival the biologics manufacturing footprints of established international biologics CDMOs.

India's Biologics Manufacturing Coming of Age
TheraNym's inauguration and Unit 2 expansion represent a significant addition to the biologics manufacturing capacity that BHC Media has been tracking across 2026: Immuneel Therapeutics' indigenous CAR-T manufacturing (covered July 17 edition), Accord BioPharma's FDA-approved pegfilgrastim biosimilar ENNUMO from Intas's India-based manufacturing (covered July 17 edition), and Laurus Labs' 21% bio CDMO revenue growth in Q1 FY27 (covered July 27 edition). Together, these stories describe an Indian biologics manufacturing ecosystem that is transitioning from small-scale, early-stage operations to commercial-scale, internationally validated facilities.

BHC Perspective
At Bengaluru Health Community, TheraNym Biologics' opening is a biologics manufacturing story that belongs alongside the NITI Aayog Bioeconomy Roadmap 2035's ambitions and the PharmaMed 2026 biological ecosystem priorities (covered in today's edition). India is building the physical biologics manufacturing infrastructure that the Great Pharma Pivot requires — and TheraNym, with its 15 KL bioreactors operational and 60,000 litre Unit 2 planned, is among the most significant new infrastructure additions in 2026.

Frequently Asked Questions
Q: What is TheraNym Biologics?
A: One of India's largest dedicated biologics CMO facilities, inaugurated by Aurobindo Pharma in Borapatla, Telangana on June 3, 2026. Features 15 KL bioreactors, advanced downstream processing, aseptic fill-finish, and quality control labs. MSD (Merck Sharp & Dohme) is the anchor customer.

Q: What is Unit 2?
A: A $150-175 million greenfield expansion of TheraNym, adding 60,000 litres of mammalian cell culture bioreactor capacity plus downstream purification — immediately following the inaugural facility's launch, anchored by an additional product schedule under TheraNym's contract manufacturing agreement with MSD.

Q: Why is TheraNym significant for India?
A: It represents India's transition from aspiration to operation in large-scale dedicated biologics contract manufacturing — combining with Laurus Labs Bio CDMO, Immuneel Therapeutics, Accord BioPharma, and others to describe an Indian biologics manufacturing ecosystem reaching commercial scale with internationally validated quality systems.